The latest plain language summary in Future Neurology provides an overview of a study looking at the investigational drug iclepertin for the treatment of cognitive symptoms in people with schizophrenia.
Using non-technical language and images, the article can help patients and their caregivers, family members, patient advocates and healthcare professionals learn more about the study.
Read the full article here.
The original article on which this summary is based is called ‘Efficacy and safety of the novel glycine transporter inhibitor BI 425809 once daily in patients with schizophrenia: a double-blind, randomised, placebo-controlled phase 2 study’ and was originally published in the journal Lancet Psychiatry in 2021. The original article can be read here.